Boston Sci heralds Emerge launch in Europe, eyes U.S., other markets

Coming off the news of its defibrillator issues (see related story) Boston Scientific ($BSX) had some good news this morning. The devicemaker has received CE mark approval and witnessed the European market launch of the Emerge PTCA dilatation catheter. The company is hoping the product will become available in the U.S. and other markets later this year. "The Emerge catheter combines several innovative balloon technologies in a single versatile platform," explains Jean Fajadet, who performed the first procedure in Europe with the catheter. "The result is a functional catheter with a low profile and excellent deliverability to facilitate the navigation and crossing of challenging coronary lesions." Boston Scientific release

Suggested Articles

The agency also gave the company’s diagnostic, run on the high-throughput Panther Fusion laboratory platform, a green light for pooled testing.

Smith & Nephew has signed up to acquire Integra LifeSciences’ orthopedics business focused on the growing upper and lower extremity markets.

The company describes the continuous glucose monitor as the world’s smallest and thinnest diabetes sensor, with a disc about the size of two pennies.